The control strategies are designed to interrupt the parasite life’s cycle by using anthelmintics, grazing management and
biological control. Triclabendazole is used against fasciolosis ininfected hosts, but a long-term use of this drug causes resistance[8–11]. Vaccine is a more cost effective, sustainable, and environ-ment friendly method for controlling the disease, and is consideredsafe to animals and consumers [12]. Immunizations with recombi-nant proteins from F. hepatica, including leucine aminopeptidasein sheep [13], cathepsin L in sheep and cattle [14,15], thioredoxinglutathione reductase in rabbit [16] and saposin-like protein 2(SAP-2) in rabbit and mice [17,18] have been shown to confer highpercents of protection against F. hepatica.Saposin-like proteins, a family of lipid interacting proteins, bindto cell membrane to induce cell lysis [19]. Fasciola spp. use thislytic proteins to cause lysis of the hosts’ erythrocytes and leuco-cytes so that their contents can be digested further for the parasites’nutrients [20]. In F. gigantica, there are 3 isoforms (SAP-1, SAP-2,and SAP-3) [21]: SAP-1 is expressed at a high level in early stagesincluding metacercariae and NEJ, whereas SAP-2 and SAP-3 areexpressed at high levels in 2-week juvenile up to adult stages, withSAP-2 being expressed more than SAP-3 [21–23]. It was shownthat rabbits vaccinated with the recombinant (r) FhSAP-2 protein exhibited up to 81.2% protection against F. hepatica infection [17].The rFgSAP-2 vaccine potential against F. gigantica has never beentested and in this report we have demonstrated a high degreeof protection by rFgSAP-2 immunization against F. gigantica in mice